| Development Stage | |||||
|---|---|---|---|---|---|
| Preclinical | Phase 1 | Phase 2 | Phase 3 | ||
| ONCOLOGY | |||||
| Monotherapy | Single Dose – Glioblastoma (GBM) Ph1/pilot | Learn more about the clinical trial | |||
| Multiple Doses1 – Glioblastoma (GBM) Ph1/2 | Learn more about the clinical trial | ||||
| Checkpoint Inhibitor Combinations | Pembrolizumab2 - Triple Negative Breast Cancer (TNBC) Ph1b/2a | Learn more about the clinical trial | |||
| Pembrolizumab3 – Solid Tumors (TNBC, NSCLC, SCLC, PanCA, MSS-CRC) Ph1b/2a | |||||
| Atezolizumab4 - High Risk Skin Cancers (MCC, cSCC, Melanoma) Ph1b/2a | Learn more about the clinical trial | ||||
| CAR-T Combinations | |||||
| INFECTIOUS DISEASES | |||||
| Monotherapy | Idiopathic CD4 Lymphocytopenia1,5 | ||||
| Adjuvant with Vaccines - Elderly Cancer Survivors Ph1/1b¹ | Learn more about the clinical trial | ||||
| ADDITIONAL DEVELOPMENT | |||||
| Monotherapy | Acute Radiation Syndrome | ||||
|
1. Investigator-initiated trial 2. Clinical Trial Collaboration with Genexine and Merck 3. Clinical Trial Collaboration with Merck. For more information, click HERE. 4. Clinical Trial Collaboration with Roche 5. Orphan Drug Designation in EU (2017. 05) and US (2019. 04) |
|||||
NeoImmuneTech provides this link as a courtesy and does not control the content of the site you are about to enter.
Do you wish to continue?